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ABSTRACT
Purpose To design and stabilize Liraglutide loaded poly (lac-
tic-co-glycolic acid) nanoparticles (PLGA NPs) proper for oral
administration.
Methods PLGA NPs were prepared by means of double
emulsion solvent evaporation method and optimized by ap-
plying 7-factor 2-level Plackett-Burman screening design.
Results Spherical shaped NPs with homogeneous distribu-
tion, 188.95 nm particle size and 51.81% encapsulation effi-
ciency were obtained. Liraglutide was successfully entrapped
in the NPs while maintaining its native amorphous nature,
and its structural integrity as well.
Conclusion Lira-PLGANPs with the required Critical Quality
Attributes (CQAs) were successfully designed by implementing a
7-factor 8-run Plackett Burman design into the extended
Quality by Design (QbD) model, to elucidate the effect of for-
mulation and process variables on the particle size, size-distribu-
tion, encapsulation efficiency and surface charge. As the devel-
oped nanoparticles maintained the native structure of the active
pharmaceutical ingredient (API), they are promising composi-
tions for the further development for the oral delivery of Lira.
KEY WORDS liraglutide . oral delivery . plackett Burman
design . PLGA nanoparticles . quality by design
INTRODUCTION
A current scenario in pharmaceutical development is inclined
towards employing rational Quality by Design (QbD) strategy
(1,2) which has been adopted by the pharmaceutical industry
to guarantee the quality of drug products (3). One of the key
elements of QbD is to identify and thoroughly understand
formulation and process variables and their effects on the crit-
ical quality attributes (CQAs), followed by the optimization of
these variables by applying an appropriate statistical design of
experiment (DOE) which enables the researcher to minimize
the number of runs and helps in identifying the most influen-
tial parameters namely; critical process parameters (CPPs)
and critical material attributes (CMAs) which may highly im-
pact the quality of the product. In addition to that,
DOE helps in identifying the optimum level of each
factor that assures the desired CQAs values, to comply
with the desired Quality Target Product Profile (QTPP)
(4). One of the important questions when implementing
DoE methodology is the selection of adequate experi-
mental design.that matches the experimental objective.
When estimating the main effects of large number of
factors are of interest to be investigated, screening de-
signs such as 2- level Plackett-Burman (PB) is applied.
The main advantage of applying such screening designs
is the minimum number of observations needed to cal-
culate the effect of several variables. If providing further
information on direct and pairwise-interaction effects
and curvilinear variable effects is desired, second order
designs: central composite designs (CCD) and Box
Behncken designs (BBD) are the most widely applied
ones (5,6). CCD provides better prediction capability than
BBD, while the latter requires fewer runs in case of 3 or 4
variables and is applied when combined factor extremes
should be avoided.
Liraglutide (Lira) or NN2211 is a recombinant palmityl-
acylated derivative of glucagon like peptide −1 (GLP1), which
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was approved for the treatment of T2DM (6) in addition to
chronic weight management (7). Lira is currently administered
once daily through subcutaneous injection which is an invasive
route known to be limited by insufficient patient adherence to
the therapy in addition to the fact that this therapeutic route is
not strictly mimicking the physiological secretion route
of GLP1 (8). The oral route should be regarded as the
most desirable choice for the delivery of Lira (9), and
realizing the dream of administering a GLP1 analog
such as Lira orally is still an elusive goal despite all advances
in peptide delivery systems.
Based on our careful evaluation of literature regarding the
emerging developments in oral delivery of antidiabetic pep-
tides (10,11), we found out that PLGA nanoparticles showed
promising results in improving the stability of peptides
through the GIT in addition to other merits of nanocarrier
systems, which can all lead to enhancing the oral bioavailabil-
ity of these peptides (12). Among the applied techniques for
preparing PLGA NPs, the double emulsion solvent
evaporation method was found to be the most prefera-
ble one, which has been efficiently used for encapsulat-
ing peptides and proteins (13–15). Nevertheless, the
physicochemical properties of nanoparticles may be af-
fected by various formulation and process parameters, which
influence the product quality.
To the best of our knowledge, there is no previously report-
ed work considering the application of DOE as a part of the
QbD strategy for the development of PLGA NPs encap-
sulating GLP-1 analog. Here we focus on the optimiza-
tion of the size and EE of the NPs as a crucial demand
along with the polydisperisity index (PDI) and surface
charge. The design space (DS) was established to opti-
mize the level of each of the examined factors, then
surface morphology, compatibility studies as well as
structural and conformational stability tests of Lira en-
capsulated in the optimized formula were conducted on
the optimized formula.
MATERIALS AND METHODS
Materials
Liraglutide was purchased from Xi’an Health Biochem
Technology Co., Ltd. (China), Poly(lactide-co-glycolide)
(PLGA 50:50, Mw= 30,000–60,000 Da), PVA (MOWIOL
4–98, MW~27,000 Da) which is a soluble polymer, and
D-(+)-Trehalose dihydrate (MW= 378.33 g/mol) were
purchased from Sigma Aldrich (Germany). D-(−)-
Mannitol was purchased from Molar Chemicals Ltd.
(Hungary). Sodium acetate anhydrous was purchased
from Scharlau Chemie S.A. (Spain). Ethyl acetate used
for dissoloving PLGA was from REANAL Labor
(Hungary). All other chemicals in the study were of analytical
reagent grade.
Methods
Preparation of Liraglutide Loaded PLGA NPs Using Double
Emulsion Solvent Evaporation Method
The preparation of Liraglutide loaded PLGA nanoparticles
was carried out by means of the double emulsionW1/O/W2-
solvent evaporation method, which is the most commonly
used technique for the encapsulation of peptide drugs within
PLGA NPs due to its simplicity and high encapsulation effi-
ciency (15,16). The amount of PLGA (30 or 60 mg) was dis-
solved in ethyl acetate at room temperature to form the or-
ganic phase. Ethyl acetate was the organic solvent of choice
here as it was reported to increase the rate of encapsulation of
hydrophilic molecules (16). The inner aqueous phase of 0.5–
5 mg liraglutide was dissolved in 0.5 ml of 1% sodium acetate
aqueous solution, it was slowly added to the organic phase,
then water/oil primary emulsion was formed upon sonication
at the power of 90 W for 30 s using a probe sonicator in ice
bath. The obtained emulsion was re-emulsified with external
aqueous phase containing 0.5–2% PVA as stabilizer by soni-
cation in ice bath at the power of 90W for 0.5–2min using the
probe sonicator. The obtained water-in-oil-in-water (W1/O/
W2) double emulsion was subjected to magnetic stirring at
room temperature over the night to allow the complete evap-
oration of ethyl acetate. The nanoparticles were then
collected by centrifugation for 15 min at 16500 rpm,
washed three times with distilled water, and resuspend-
ed in deionized water.
For the lyophilization process, 1.5 ml of each nanoparticles
suspension was poured into semi-stoppered glass vials
with slotted rubber closures and freeze-dried at −40°C
for 72 h. 5–10% mannitol or trehalose was added as
lyoprotectants. The chamber pressure was maintained at
0.01 mbar, and the process was controlled by (Scanlaf
CTS16a02) software.
Design of Experiment Study Using Plackett Burman Design
PB design is the most widely used method among the various
screening designs used for the determination of the most in-
fluential factors affecting the pharmaceutical development as
it has many advantages: it screens a large number of variables
and identifies the highly influential ones with relatively few
runs, while assuring a good degree of accuracy. PB design with
a total of 8 runs involving 7 independent variables was carried
out using STATISTICA 13 software, and analysis of variance
(ANOVA) was applied to determine the statistical significance
of each model coefficient, which was significant at 95% level
(P< 0.05).
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The linear equation of this model is:
Y ¼ b0 þ b1X1 þ b2X2 þ b3X3 þ b4X4 þ b5X5 þ b6X6
þ b7X7
where Y is the response, b0 is the constant and b1, b2…b7 are
the coefficient of factors X1, X2…X7. It is known that a pos-
itive value of the regression coefficient is an indicator of a
positive effect of the factor (X) on the response (Y), while a
negative value refers to an inverse relation between the exam-
ined variable and the response (17).
Depending on our previous risk assessment-based investi-
gation (18–20), the selected independent formulation and pro-
cess variables were: PLGA amount (X1), liraglutide amount
(X2), 2nd sonication time (X3), PVA concentration (X4),
lyoprotectant type (X5), lyoprotectant concentration (X6)
and external aqueous phase to organic phase w2/o ratio
(X7). Particle size (Y1), PDI (Y2), EE (Y3) and zeta potential
(Y4) were selected as dependent variables. The examined low-
er and upper levels of the independent factors X1-X7
(Table 1) were also determined depending on preliminary
experiments and literature survey.. The design was val-
idated by 3 extra center checkpoint formulations and
the bias (%) between predicted and observed values of
response was calculated. The optimized formulation was
prepared within design space (DS) and compared with pre-
dicted results of the responses.
Characterization of the Prepared Liraglutide Loaded PLGA NPs
Particle Size, S ize Distr ibution and Surface Charge
Measurements. Approximately 5 mg of the prepared
freezedried NPs was dispersed in 5 ml of double distilled water
and sonicated to minimize the possible inter-particle interac-
tions. The hydrodynamic diameter (Z-average), PDI and zeta
potential of reconstituted NPs were measured in folded capil-
lary cell by using Malvern Nano ZS Zetasizer (Malvern
Instruments Ltd. UK) equipped with He-Ne laser(633 nm).
The instrument allows the particle size measurement in the
range of 0.3 nm-10.0 μm using patented NIBS (Non-Invasive
Back Scatter) technology, with high accuracy of ± 2%. The
samples were measured at 25°C, the refractive index
was 1.445, and the number of scans was 17. All the
measurements were conducted in triplicate and the average
value of each was used.
Encapsulation Efficiency (EE). The encapsulation efficiency of
liraglutide encapsulated in PLGANPs was determined direct-
ly using the centrifugation method. In this method, 20 mg
from each NPs formulation was dissolved in 2 ml of DCM,
then liraglutide was extracted into 4 ml of PBS (pH = 8.1),
soaked for 30 min and then centrifuged at 16500 rpm at
4οC for 15 min. The supernatant was then collected and the
amount of encapsulated liraglutide in the supernatant was
measured using the RP-HPLC method. Samples were run
in triplicate.
The percentage of EE was calculated using the following
equations:
EE% ¼ encapsulated amount of liraglutide=
total amount of liraglutide added* 100:
Chromatographic Equipment and Conditions. Reversed phase
HPLC (Shimadzu Corporation, NEXERA X2, Tokyo,
Japan) method was developed in our lab to analyze liraglutide.
A Kinetex ® C18 column with dimensions of (5 μm,
150*4.6 mm, (Phenomenex, USA) was used as a stationary
phase. The flow rate of 1.5 ml/min was set over 15min with a
mobile phase comprised of 0.02 M aqueous KH2PO4 solu-
tion (pH= 7.0, solvent A) and acetonitrile (solvent B). The
mobile phase was pumped in a gradient mode as it was
changed from 80:20 (A:B, v/v) to 30:70 (A:B, v/v) in 12 min
then going back to 80:20 (v/v) between 12.1–15 min. The
column temperature was set to 40°C, and the sample tray
temperature was set to 15°C. Fifty microliters of sample vol-
ume was injected. The wavelength of UV detection was
214 nm.. The retention time of liraglutide is 8.65 min.
In our HPLC method, some chromatographic parame-
ters have been calculated. The limit of detection (LOD)
value of the liraglutide is 0.175 ppm, the limit of quan-
tification (LOQ) value is 0,530 ppm, respectively.
Capacity factor (k’) for liraglutide is 5.20, the asymme-
try factor of the peak of liraglutide showed 1.40 value,
respectively. The theoretical plate (N) value is 146,620,
calculated by the Ph.Eur. guideline. The regression of
the linearity (R2) of the liraglutide calibration curve was
0.996, respectively.
Scanning Electron Microscopy Measurements (SEM). To inves-
tigate the surface morphology, sphericity, and discreteness of
the freeze dried NPs containing lira, scanning electron
Table 1 Levels of the Selected Critical Factors
Critical factor Low level High level
PLGA amount (mg) X1 30 60
Liraglutide amount (mg) X2 0.5 5
2nd sonication time (min) X3 0.5 2
PVA (%) X4 0.5 2
Lyoprotectant type X5 Mannitol Trehalose
Lyoprotectant (%) X6 5 10
W2/O ratio X7 2 5
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microscopy (SEM) (Hitachi S4700, Hitachi Scientific Ltd.,
Tokyo, Japan) at 10 kV was used. The samples were coated
with gold-palladium (90 s) with a sputter coater (Bio-Rad SC
502, VGMicrotech, Uckfield, UK) using an electric potential
of 2.0 kV at 10 mA for 10 min. The air pressure was 1.3–
13.0 mPa. 3 repetitions of the optimized formula were tested
by SEM technique and images were captured from different
surface regions of each sample and at two different magnifi-
cations (×15,000, ×45,000).
Compatibility Studies
To investigate the physicochemical compatibility between the
drug and the polymer in the prepared PLGA NPs, FTIR,
DSC and XRD analysis were conducted.
Fourier Transform Infrared Spectroscopy (FTIR). The FT-IR
spectra of pure Lira, PLGA, Lira free/loaded PLGA
NPs were recorded using FT-IR spectrometer (Thermo
Nicolet AVATAR; LabX Midland, ON, Canada) in the
range of 4000 and 400 cm−1 with an optical resolution
of 4 cm−1. The sample was mixed with 150 mg of dry
KBr and compressed to prepare the pellet.
Differential Scanning Calorimetry (DSC). To define the physical
state of the peptide drug in the nanoparticles and assess
any possible intermolecular interaction between the drug
and the polymer in the nanoparticles, DSC studies of
pure Lira, PLGA, Lira free/loaded PLGA NPs were
performed using (Mettler Toledo TG 821e DSC
Mettler Inc., Schwerzenbach, Switzerland). Accurately
weighed samples (3–5 mg) were sealed in an aluminum
pan and an empty pan was used as a reference. The
samples were analyzed at a scanning temperature from
25 to 300°C at a heating rate of 10°C/min under ni-
trogen purge. Data analysis was performed using the STARe
software (Mettler Toledo Mettler Inc., Schwerzenbach,
Switzerland).
X-Ray Diffraction Study (XRD). XRD is a useful technique ap-
plied herein to characterize the physical state of liraglutide
entrapped in PLGA NPs and further to confirm the
stability attributed to polymer-drug interaction. Powder
X-ray diffraction (XRD) patterns of pure Lira, PLGA,
Lira free/loaded PLGA NPs were obtained using an X-
ray powder diffraction (XRPD) BRUKER D8 Advance
X-ray diffractometer (Bruker AXS GmbH, Karlsruhe,
Germany), supplied with a Cu K λ1 radiation source
(λ= 1.54056 A°), with a voltage of 40 kV and a current of
40 mA, in flat plate θ/2θ geometry, over the 2θ ranges 3–40°,
with a scan time of 0.1 s at step size of 0.007°. The sample was
placed on a quartz holder and measured at ambient temper-
ature and humidity.
Stability of Lira Encapsulated in PLGA NPs
Electrospray Ionization Mass Spectrometry. Electrospray
Ionization Mass Spectrometry (ESI-MS) is a valuable tool to
be used to provide information about the molecular weight of
native Lira and compare it to Lira loaded in NPs. Lira was
characterized by an Agilent 1100 LC-MSD trap mass spec-
trometer equipped with an electrospray ion source.
Circular Dichroism. CD was performed to evaluate the confor-
mational stability of Lira loaded into the prepared polymeric
NPs. CD spectra were obtained with a Jasco J-1100 spectro-
polarimeter (Tokyo, Japan). Aliquot of each of PBS (pH =
8.1), native Lira in PBS and Lira extracted from NPs in PBS
was placed in a 10 mm pathway Far-UV quartz cuvette and
the Far-UV CD spectra were collected by an PM-539 CD
spectrometer. Spectra were collected at room temperature
over the wavelength range of 260 nm to 195 nm with
0.2 nm interval. Ellipticity was recorded at scanning speed of
100 nm/min and 1.00 nm band with 5 accumulations. PBS
solution subtraction, noise reduction and data analysis were
performed using standard analysis and temperature/
wavelength analysis programs (Jasco).
RESULTS AND DISCUSSION
Placket Burman Design: Risk Analysis
The QTPP that encompasses the desired CQAs was defined
in our previous paper as following: stable, homogeneous and
spherical shaped freeze dried NPs with particle size of 100-
300 nm and maximum EE. Risk assessment was also conduct-
ed (using LEAN-QbD software) for ranking and prioritizing
CMAs and CPPs likely to have an impact on the quality of
Lira loaded PLGA NPs (20) and the highly influential param-
eters were prioritized and subjected to subsequent screening
using a seven-factor, two-level, eight-run PB screening design
(Table 2) in order to minimize their risk to a low level by
controlling these variables in a specific accepted range.
Herein, the possible effects of these formulation and pro-
cess parameters on four responses namely: mean particle size,
PDI, EE and zeta potential were investigated by applying the
PB screening design where the experimental data were vali-
dated by ANOVA for each factor. ANOVA parameters for
predictingmean particle size (Y1), PDI (Y2), EE (Y3) and Zeta
potential (Y4) are presented in Supplemental Table 1.Surface
response plots are also useful diagrammatic representation of
the values of the response, to project the significance of effects
for each variable and can explain the relationship between
tested independent factors and dependent responses. A
color-scale object along with the surface plot serves as a leg-
end, and the value of the response is dependent on the gradual
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color. Based on this color gradient, these plots can present the
change in response value with different levels of the indepen-
dent variable.
Influence of Investigated Parameters on the Z-Average
Size, PDI, EE and Zeta Potential
Depending on the selected parameters levels, the Z-average
ranged between 160.1 ± 5.6 nm and 235. ± 5.3 (Table 3). The
corresponding coefficients are summarized in Supplemental
Table 2, where the factors a P value<0.05 are regarded as
highly significant, while the ones having nonsignificant
response coefficients with a P value>0.05 are least con-
tributing in the prediction of mean particle size. The
polynomial equation obtained for the fitted full model
explaining the effect of formulation and process variables on
the mean particle size is:
Y1¼197:8021þ9:5079X1 þ 1:5304X2 þ 7:7638X3
−16:9754X4−5:4712X5−3:5429X6−7:0791X7
with R2 ¼ 0:9745; adjusted R2 ¼ 0:9609;
and Mean square MSð Þ ¼ 22:3978
According to this polynominal equation and the Pareto
chart (Fig. 1), the most influential factors in terms of particle
size are the PVA concentration, PLGA amount followed by
sonication time and W2/O ratio at almost the same level of
significance. Then the next important variables include
lyoprotectant type and concentration. The tested levels of
Lira amount were observed to have a non-statistically signifi-
cant effect on the mean particle size.
In all prepared formulations, NPs exhibited a practically
monodisperse or narrow distribution (21) as PDI was ranged
from 0.1 ± 0.003 in PBD-F6 to 0.22 ± 0.01 in PBD-F3
(Table 3) evidencing that the obtained NPs are homogeneous
and stable with no aggregation. Figure S1 shows an example
of PDI = 0.07 with Z-average = 157.1 nm obtained for PBD-
F1. The polynomial equation obtained for the full model
describing the effect of formulation and process variables on
the PDI value is:
Y2 ¼ 0:1568−0:0061X1þ 0:0312X2þ 0:0005X3
−0:0013X4−0:0032X5−0:0031X6þ 0:0291X7
with R2 ¼ 0:9235; adjusted R2 ¼ 0:8828;
and Mean square MSð Þ ¼ 0:0003
Y2 ¼ 0:1568−0:0061X1þ 0:0312X2−0:0032X5
−0:0031X6þ 0:0291X 7………Redcuced modelð Þ
with R2 ¼ 0:92256; adjusted R2 ¼ 0:89522; and
Mean square MSð Þ ¼ 0:0002:
The statistical analysis (Table 3S) along with the Pareto
chart (Fig. 3) revealed that only two of the examined CMAs
namely Lira amount andW2/O ratio were observed to have a
significant effect on the PDI value.
Depending on the tested two levels of each factor, the re-
sults showed that EE varied between 20.1 ± 1.7 in formulation
PBD-F1 and 43.5 ± 3.3in PBD-F4 (Table 3).The polynomial
equation obtained for the fitted full model showing the impact
of the seven examined variables on EE is:
Table 3 Experimental Responses Results in PBD
Run code Z-AVE
(nm)
PDI EE% Z-potential
(mV)
PBD-F1 160.1 ± 5.6 0.10± 0.03 20.1 ± 1.7 −30.6 ± 1.8
PBD-F2 209.8 ± 8.01 0.15± 0.01 36± 1.25 −25± 1.6
PBD-F3 190.0 ± 2.8 0.23± 0.01 41± 2.46 −27.3 ± 0.7
PBD-F4 200.2 ± 3.5 0.16± 0.03 43.5 ± 3.34 −31.2 ± 1.2
PBD-F5 179.5 ± 3.8 0.17± 0.01 32± 4.03 −23.8 ± 1
PBD-F6 235.7 ± 5.3 0.10± 0.003 28.9 ± 2.05 −29.2 ± 0.4
PBD-F7 223.6 ± 3.7 0.17± 0.02 22.2 ± 2.12 −30.4 ± 0.
PBD-F8 183.5 ± 3.03 0.20± 0.01 21± 1.51 −26± 0.2
Table 2 The Input Factor Levels in 7 Factor, 2 Level, 8 Run PBD
Run code PLGA (mg) Lira (mg) 2nd sonication time (min) PVA (%) Lyoprotectant type Lyoprotectant (%) W2/O ratio
PBD-F1 30 0.5 0.5 2 Trehalose 10 2
PBD-F2 60 0.5 0.5 0.5 Mannitol 10 5
PBD-F3 30 5 0.5 0.5 Trehalose 5 5
PBD-F4 60 5 0.5 2 Mannitol 5 2
PBD-F5 30 0.5 2 2 Mannitol 5 5
PBD-F6 60 0.5 2 0.5 Trehalose 5 2
PBD-F7 30 5 2 0.5 Mannitol 10 2
PBD-F8 60 5 2 2 Trehalose 10 5
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Y3 ¼ 30:548þ 1:7683 X1 þ 1:3458X2−4:5825X3
−1:4458X4−2:8408X5−5:7483X6 þ 1:915X7
with R2¼0:9471; adjusted R2 ¼ 0:9189;
and Mean square MSð Þ ¼ 6:5021:
This equation along with the Pareto chart (Fig. 1) and
statistical analysis (Table 4S) show that the lyoprotectant %,
2nd sonication time and lyoprotectant type are the most high-
ly risky factors in terms of EE. This is followed by other factors
which all show a significant impact on the amount of Lira
encapsulated in the PLGA NPs.
The zeta potential was also monitored during the optimi-
zation steps and its values ranged from-31.2 ± 1.2 mV in
PBD-F4 to −23.8 ± 0.95 mV in PBD-F5 (Table 3), and these
expected negative values are attributed to the presence of
carboxyl group end on PLGA. Figure S2 depicts the result
of zeta potential obtained for formulation PBD-F1 as an ex-
ample. The full model describing the effect of formulation and
process variables on the zeta potential is:
Y4¼−28:0596−0:0154X1−0:9071X2 þ 0:4496X3
−0:0646X4−0:4679X5−0:1663X6 þ 2:2846X7
with R2 ¼ 0:9001; adjusted R2 ¼ 0:8468;
and Mean square MSð Þ ¼ 1:1599
Y4 ¼ −28:0596−0:9071X2þ 0:4496X3−0:4679X5
−0:1663X6þ 2:2846X7…………Reduced modelð Þ
with R2 ¼ 0:89946; adjusted R2 ¼ 0:86397;
and Mean square MSð Þ ¼ 1:0:297:
It is obvious from the statistical analysis (Table 5S) and the
Pareto chart (Fig. 1) that only the W2/O ratio and the
lira amount had a significant impact (P < 0.05) on the
surface charge of PLGA NPs. Other examined variables
were observed to have only a non-significant effect on
surface charge.
The effect of the above-explained variables on Y1,Y2,Y3
and Y4 is discussed point by point in the following:
Pareto Chart of Standardized Effects; Variable: SIZE
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(8)W2/O
(4)Sonication time
(2)PLGA amount
(5)PVA %
Pareto Chart of Standardized Effects; Variable: PDI
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(4)Sonication time
(5)PVA %
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(3)Lira amount
Pareto Chart of Standardized Effects; Variable: EE
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(4)Sonication time
(7)Lyoprotectant conc.
Pareto Chart of Standardized Effects; Variable: ZETA POTENTIAL
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2.05
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p=.05
Standardized Effect Estimate (Absolute Value)
(2)PLGA amount
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(6)Lyoprotectant type
(3)Lira amount
(8)W2/O
Fig. 1 Pareto charts of the effects of the examined independent variables on Z-average size (Y1), PDI (Y2), EE (Y3), zeta potential (Y4). Replicate refers to
number of repetitions for each formula which was 3.
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Effect of Polymer Amount
It is apparent from Fig. 2 that when the PLGA amount was
increased, the Z-average increased correspondingly, as sup-
ported by many earlier published papers (22,23) That could
be explained by increasing the viscosity of the organic phase
which leads to a reduction in the net shear stress (24), in ad-
dition to a reduction in the evaporation rate; i.e. the dispersion
rate of the organic phase toward the external aqueous phase
will be slower, thus that incites the formation of larger particles
(25,26). The formation of a more viscous organic phase was
reported to push up the frequency of collisions between par-
ticles during the emulsification and droplet solidification step,
which may lead to the aggregation of the semisolid particles
(5). Regarding the PDI value, it was also observed that size
distribution was slightly decreased by increasing the PLGA
amount which means that a greater level of PLGA would
promote the formation of much more homogeneous NPs.
The positive effect that the PLGA amount has on EE
(Fig. 4) could be again due to the fact of increasing the viscosity
of the organic phase with a higher amount of polymer, which
can retard drug diffusion into the external aqueous phase and
thus increase the amount of drug entrapped inside the NPs
(27,28). It is also known that larger nanoparticles obtained
with a higher PLGA level can provide sufficient surface for
entrapping the peptide drug. Furthermore, higher PLGA
levels give rise to more rapid polymer deposition as ethyl
acetate is removed from the NPs, which is expected to
hinder any undesirable Lira diffusion into the external
phase (29).
Effect of Liraglutide Amount
The positive effect that Lira has on the 2nd emulsification and
both final particle size (Fig. 2) and size distribution as a result
(Fig. 3) would be explained by the influence of the drug on the
droplet size of the inner aqueous phase within the organic
phase in the first water-in-oil (w1/o) emulsion, which may
modify its ability for dispersion in the outer aqueous phase.
However, this effect was only limited and not significant in the
case of particle size, while Lira theoretical loading amount was
a significant influential parameter affecting the PDI and zeta
potential values (Fig. 1, Fig. 3, Fig. 5). The Lira level was also
shown to have a significant positive effect on EE; when loading
higher amount of Lira, EE was even higher (Fig. 4). This
positive trend was previously reported with other peptide
drugs as insulin, and it is explained due to higher amount
of peptide that is associated with the surface of nanopar-
ticles and is electrooptically linked to a greater extent (30),
thus resulting in a higher EE value. However, the studied
levels of the Lira amount in our work were shown to be
the least risky factor affecting EE as presented in the
Pareto chart (Fig. 1).
 > 220 
 < 220 
 < 210 
 < 200 
 < 190 
 < 180 
 < 170 
 > 210 
 < 210 
 < 200 
 < 190 
 < 180 
 > 210 
 < 206 
 < 196 
 < 186 
Fig. 2 Surface plots showing the effect of the significant examined variables
on the Z-average size (Y1).
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Effect of PVA Concentration
PVA has previously proved to be a good choice as a surfactant
used to prepare stable PLGA NPs with a small size and a
narrow PDI due to its ability of minimizing the surface tension
of the continuous phase which is an aqueous phase in our
work. The statistical analysis of the results showed that increas-
ing PVA level played a crucial role in decreasing particle size
 > 0.22 
 < 0.21 
 < 0.19 
 < 0.17 
 < 0.15 
 < 0.13 
 < 0.11 
 < 0.09 
Fig. 3 Surface plot showing the
effect of lira amount andW2/O ratio
on PDI (Y2).
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 > 35 
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 < 27 
 < 22 
 > 35 
 < 34 
 < 29 
 < 24 
 > 35 
 < 32 
 < 27 
 < 22 
Fig. 4 Surface plot showing the effect of examined variables on EE (Y3).
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(Fig. 2), and it was the leading factor impacting the size of NPs
as can be seen in the Pareto chart (Fig. 1) which is in agree-
ment with previous reports (31,32) .This result can be expect-
ed from the stabilizing function of PVAmolecules that tend to
align themselves at the droplet surface lowering the free
energy at the interface between two phases and avoiding co-
alescence between nanodroplets, thus stabilizing the smaller
droplets and preventing coalescence into a larger one (33,34).
Hence, at a low PVA concentration, a larger particle size was
obtained due to insufficient reduction in interfacial tension. It
Table 4 The Observed and the Predicted Values of the Response Values of the Center Checkpoints
Experimental 
response
Predicted 
value
Observed value
(F1)
Bias%
Observed value
(F2)
Bias%
Observed value
(F3)
Bias%
Intermediate 
precision (%)
Z-average 
(nm)
197.8 195.8±2.5
1.0
202.7±5.8
2.5
196.4±4.1
0.7
3.8
EE% 30.5 29.5±1.8 
3.3
31.2±2.2
2.3
33.1±3.3
8.5
1.8
PDI 0.20 0.19±0.01
5.0
0.19±0.01
5.0
0.18±0.003
10.0
0.01
Zeta 
potential 
(mV)
-28.1 -28.1±1.1
0
-28.8±1
2.5
-27.7±1.3
1.4
0.6
 > -25 
 < -25 
 < -26 
 < -27 
 < -28 
 < -29 
 < -30 
 < -31 
Fig. 5 Surface plot showing the
effect of lira amount andW2/O ratio
on zeta potential (Y3).
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was also reported that a fraction of PVA remains associated
with the surface of nanoparticles even after the washing of
nanoparticles (33). Thus, the presence of the PVA layer on
the surface of nanoparticles may also improve their stability
during the freeze-drying process.
It is also clear that as PVA level increased from 0.5% to
2%, EE decreased (Fig. 4). A possible explanation of this neg-
ative impact was discussed in a preceding published work, as it
was proved that the breakdown of the inner aqueous droplets
containing Lira took place along with the fragmentation of the
organic phase because of the cavitation occurs in the complex
system of three phases, the higher level of PVA in the external
aqueous phase is attributed to enhancing the breakdown of
inner aqueous droplets and a higher amount of Lira can es-
cape to the external phase as a result (34). This is sup-
ported by a previous paper in which increasing the
emulsifier concentration had led to lower entrapment
of the protein drug in PLGA NPs, which was explained as a
result of increasing the partitioning of the drug from the inner
to the outer phase (35).
Effect of 2nd Sonication Time
The results revealed that larger and less homogeneous parti-
cles were yielded when increasing 2nd sonication time from
30 s to 2 min (Fig. 1, Fig. 2). This could be explained as
follows: at the beginning, increasing the sonication time led
to the formation of smaller droplets due to the production of
higher energy and higher shearing rates, which are more effi-
cient in breaking large droplets into smaller ones (36).
However, a further elevation in this sonication period resulted
in the re-aggregation of these particles. This trend is in accor-
dance with results obtained by others where they observed the
formation of larger droplets as an outcome of longer sonica-
tion or homogenization time (37). Besides, the longer the 2nd
sonication time, the higher the shear energy input, thus the
higher the leached amount of peptide from W1/O to
the external aqueous phase i.e. the lower the EE. The
Pareto chart (Fig. 1) demonstrates that the prolonged 2nd
sonication time was the 2nd highest risky factor regarding
the influence on EE.
Effect of Lyoprotectant Type and Concentration
Lyoprotectant are commonly used to stabilize the particles
and protect them from degradation during freeze-drying
and storage (38). Regarding the type of lyoprotectant used in
this study, these significant changes in particle size may be
related with the behavior of each lyoprotectant during
freeze-drying, and the adsorption of lyoprotectant on the sur-
face of nanoparticles. It is clear that trehalose is more effective
in obtaining smaller nanoparticles (Fig. 1, Fig. 2).This is in
accordance with previous papers that confirmed that trehalose
which is a non-reducing sugar could be the most preferable
lyoprotectant of choice because of its merits over the other
sugars; including a very low chemical reactivity, a higher glass
transition temperature Tg, less hygroscopicity, in addition to
the absence of internal hydrogen bounds, allowing a more
flexible formation of hydrogen bonds with nanoparticles dur-
ing the freeze-drying process (39). However, mannitol
was proved to be more effective in obtaining a higher
EE value according to our experimental work.
Trehalose was investigated before regarding its effect
on the secondary structure of insulin, and the results
showed that it highly affected the conformational stabil-
ity of the peptide; so it might not be the best choice to
encapsulate peptide drugs (40). In addition to that; man-
nitol is able to form crystal morphology (which is confirmed
later in this paper by DSC and XRD) and this might be
attributed to the stability of peptide.
When it comes to the lyoprotectant level, results revealed
that increasing this level up to 10% significantly reduced the
Z-average and slightly minimized the PDI of the obtainedNPs
(Fig. 1,Fig. 2), which means that at this level the used
lyoprotectants are more efficient in preventing the aggrega-
tion and stabilizing the PLGA NPs the use of an excess
amount of lyoprotectant might eventually make it reach the
limit of its stabilization ability and thus the agglomeration of
NPs is likely to increase (41). It is also apparent from the
statistical analysis presented in the Pareto chart and surface
plot (Fig. 1, Fig. 4) that the lyoprotectant level was the most
influential formulation variable impacting EE. When the level
of lyoprotectant continued increasing, the amount of
entrapped Lira significantly decreased, which could be
the result of smaller NPs obtained with a higher
lyoprotectant level, and thus less sufficient surface area
for entrapping the drug.
Effect of W2/O Ratio
As the volume ratio of external aqueous phase to organic
phase W2/O went on increasing, which was achieved by in-
creasing the volume of the external aqueous phase, the aver-
age particle size was significantly decreased as can be seen
from the Pareto chart and surface plot (Fig. 1, Fig. 2). This
formation of smaller droplets may be due to the higher
amount of stabilizer present as compared to the non-
sufficient amount of stabilizer when using a lower amount of
this phase. It was also recently reported that increasing the
continuous phase volume:organic phase ratio had led to par-
ticle size reduction (27).
Regarding PDI values, a significant increase in size distri-
bution was observed when the volume of the external aqueous
phase was higher, as shown by the Pareto chart and surface
plot (Fig. 1, Fig. 3). This observation might be attributed to a
reduction of shear stress during the homogenization process
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(42). Besides, the phase ratio was the highly influential factor
affecting the surface charge as increasing the external aqueous
phase volume led to a significant increase in the zeta potential
value (Fig. 5).
The EE exhibited a significant upward trend when increas-
ing the volume of the external aqueous phase, as presented in
the Pareto chart and surface plot (Fig. 1,Fig. 4). The impact of
the external aqueous phase/organic phase is controversial, as
X1          X2        X3        X4       X5         X6      X7
Fig. 6 The desirability plots and graphical design space representing the optimum levels of factors required to prepare the optimized formula.
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many papers reported that increasing the W2/O ratio can
lead to minimizing the amount of the encapsulated drug
(31,42). However, other published papers assumed that a rel-
atively higher volume ratio of the external aqueous phase was
beneficial for maximizing the drug encapsulated in the NPs as
a higher outer aqueous phase volume can speed up the solid-
ification time (evaporation of ethyl acetate and formation of
NPs), while the smaller the volume of this outer aqueous
phase, the longer the time required for solidification, thus over
this time Lira may leak to the outer phase due to its hydrophi-
licity (43).
Placket Burman Design: Model Validation
The three replications of center checkpoint formulations were
prepared and evaluated for the particle size, EE, PDI and zeta
potential to evaluate the reproducibility of the generated
models and estimate the experimental error. Table 4 presents
the percentage of bias between predicted and observed
values for each response was calculated by means of the
following equation .
Bias %ð Þ ¼ Predicted value−observed valueð Þ=Predicted value*100
The minor differences between the predicted values and
the average of experimental values confirm the validity of this
design in providing a good prediction of the four tested
responses.
In addition to that, the calculated relative standard devia-
tion RSD% values that are presented in Table 4 prove the
repeatability and intermediate precision regarding the 4 re-
sponses that further confirms high analytical process
variability.
Placket Burman Design: Design Space
and Optimization
After establishing the polynomial equations describing the re-
lationship between the CPPs, CMAs and the examined re-
sponses namely; particle size, EE, PDI and zeta potential,
the optimization process was conducted. Among the four re-
sponses, size and EE were the highly critical quality attributes
of nanoparticles being significantly affected by almost all the
tested variables which is in accordance with the estimated
severity scores of CQAs that was calculated previously at the
initial risk assessment process. Therefore, the deign space (DS)
was optimized (Fig. 6) targeting the following criteria: the par-
ticle size was minimized, encapsulation efficiency was maxi-
mized while PDI and Zeta potential were excluded. Thanks to
the knowledge obtained via the DS, the optimum levels of the
formulation factors were determined: 60 mg of PLGA, 5 mg
of Lira, 0.5 min 2nd sonication time, 1.48% of PVA, 5% of
mannitol and W2/O ratio of 5.As shown in Table 5, the
observed values were comparable to the predicted ones, pre-
senting another confirmation of the validity of the generated
Table 5 The Observed and the
Predicted Values of the response
values of the Optimum Lira
Nanoparticle
Experimental response Predicted value Observed value Residual Bias (%)
Z-average (nm) 197.9 189± 4.99 8.95 4.5
EE% 48.3 51.8 ± 2.39 3.5 7.2
PDI 0.21 0.19± 0.012 0.034 7.8
Zeta potential (mV) −26.5 −27.1± 1.33 0.58 2.2
Fig. 7 SEM images of liraglutide loaded PLGA NPs.
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models and indicating that the optimized formulation is
reliable.
Scanning Electron Microscopy (SEM)
Figure 7 depicts the shape and surface morphology of the
optimized Lira loaded PLGA NPs visualized by SEM. Since
the optimized formula was homogeneous (in accordance with
low PDI) we selected two images as representative for the
sample. The results revealed that Lira loaded PLGANPs were
spherical with quite a smooth surface and they had homoge-
neous distribution which is in agreement with the above-
mentioned results that demonstrated low PDI values for all
formulations.
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Fig. 8 Mass spectra of lira extracted from PLGA NPs compared to native lira.
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Compatibility Studies
Fourier Transform Infrared Spectroscopy (FTIR)
Figure S3. represents the FTIR spectra of pure Lira, pure
PLGA and Lira free/loaded PLGA NPs.
The amide I region (1710–1590 cm−1) is the most represen-
tative region of the spectra to assess peptide or protein based drug
secondary structure (44). In the FTIR of pure Lira, the amide I
band was located at 1655 cm−1 and was assigned to C=O
stretching, while the amide II band was observed at 1541 cm−1
(in-planeN–Hbending component andC–N stretching bands of
the amide bond). Besides, the typical peak at 2928 cm−1 was
ascribed to C-H stretching of CH3, and the peak at 1396 cm−1
is attributed to amide III. When analyzing the FTIR spectra of
Lira loaded PLGA NPs, it was found that the major peaks of
pure Lira assigned to amide I and II and III were masked by the
PLGA bands, and this seems to be a logical result since the
amount of PLGA was much higher than the Lira amount in
these NPs. There were no clear differences between the spectra
of the blank NPs and Lira loaded NPs which is also expected as
the drug loading is very small when compared to the polymer
amount. These observations suggest that Lira was successfully
loaded into the PLGA NPs.
Differential Scanning Calorimetry (DSC)
Figure S4 represents the DSC thermograms for pure Lira,
PLGA, liraglutide free/loaded PLGA NPs. For the temperature
range examined, the PLGA thermogram exhibited a glass tran-
sition point at 49.22°C and no melting endothermic peak was
observed, as PLGA appears amorphous in nature. The DSC
thermogram of pure Lira revealed a peak at 275.46°C, which
is attributed to the thermal degradation of this peptide drug, and
no endothermic peak of melting was shown, which proved the
amorphous nature of the drug. Since the thermogram of Lira
loaded PLGA NPs did not display any extra endo/exothermic
peaks compared to the blank NPs, this is an indicator of the
presence of Lira in the amorphous phase and this drug is suc-
cessfully encapsulated into the PLGA matrix.
X-Ray Diffraction Study (XRD)
XRD studies further verified the amorphous nature of both
PLGA and pure Lira as they showed no characteristic peaks in
their diffractograms which is in accordance with the results of
DSC thermograms (Fig. S4). As depicted in Fig. S5, mannitol
remained in crystalline state after freeze drying which is due to
the property of mannitol to recrystallize at low cooling rates
rather than rapid cooling. The crystallization of this lyoprotectant
could have a negative effect on the stability of NPs as it is able to
limit the formation of these hydrogen bonds (30), and this can
explain why trehalose was more efficient than mannitol at
preventing the aggregation of NPs and thus minimizing the Z-
average. There was no difference between the diffractograms of
the loaded and blank PLGANPs which is explained in literature
as a result of the successful encapsulation of the peptide drug
inside the polymeric nanoparticles without change in its physical
state (45), and this is in accordance with the DSC results.
Structural Stability
ESI-MS
MS was used to compare the molecular weight MW of lira
standard (native) to lira extracted from PLGA NPs. As the spec-
tra in Fig. 8 depicts, the measured MW of native Lira and Lira
loaded in NPs are almost equal, and the spectra confirmed
the presence of Lira with a molar mass of 3751 Da which is
an evidence of the integrity of Lira loaded in PLGA NPs
prepared using the optimized formulation and process
parameters.
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Fig. 9 CD spectra of lira extracted
from PLGA NPs compared to
native lira.
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CD
Since the preservation of the secondary structural integrity of
a peptide drug in the nanocarrier is critical for its biological
efficacy, the secondary structure of Lira extracted from NPs
was compared to that of native Lira. The CD spectra of native
Lira (Fig. 9) showed two minima at 208.8 nm and 218.4 nm
indicating the presence of alpha helix elements in the struc-
ture, which is in consistent with previous studies on the typical
structure of the glucagon-like peptide-1 family. No significant
conformational change was recorded for Lira extracted from
PLGANPs (in PBS, pH= 8.1) as the far UVCD spectra for it
showed two minima at 209.4 nm and 219.2 nm, and almost
entirely overlapped with the CD spectrum for the standard.
CONCLUSION AND FUTURE PERSPECTIVES
The present study is the first published work that substantiated
the application of rational QbD-based methodology for the op-
timization of a GLP-1 analog loaded nanocarrier system. This
work demonstrated the importance of implementing DOEwith-
in QbD philosophy in the early stage of Liraglutide containing
NPs development due to the complexity of this system.
After establishing the design space, with the minimum par-
ticle size and maximum EE, the optimized formula was suc-
cessfully prepared meeting the targeted CQAs. This opti-
mized Lira loaded PLGA NPs formula was also successful in
maintaining the native structure of Lira and could be prom-
ising for the oral delivery. Thus, in vitro release kinetics, cyto-
toxicity, intestinal permeability and in vivo studies will be fur-
ther conducted on this formula.
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